Extracorporeal photopheresis for the treatment of refractory Crohn's disease: Results of an open-label pilot study

Inflammatory Bowel Diseases

Volumn 15, Issue 6, 2009, Pages 829-836

  Abreu, Maria T ^a,o   von Tirpitz, Christian ^b   Hardi, Robert ^c   Kaatz, Martin ^d   Van Assche, Gert ^e   Rutgeerts, Paul ^e   Bisaccia, Emil ^f   Goerdt, Sergi ^g   Hanauer, Stephen ^h   Knobler, Robert ⁱ   Mannon, Peter ^j   Mayer, Lloyd ^k   Ochsenkuhn, Thomas ^l   Sandborn, William J ^m   Parenti, Dennis ⁿ   Lee, Kevin ⁿ   Reinisch, Walter ⁱ  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ULM   (Germany)

^c Chevy Chase Clinical Research   (United States)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f MORRISTOWN MEMORIAL HOSPITAL   (United States)

^g UNIVERSITY OF MANNHEIM   (Germany)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ UNIVERSITY OF VIENNA   (Austria)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^k MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF MUNICH   (Germany)

^m MAYO CLINIC   (United States)

ⁿ Therakos   (United States)

^o NONE   (United States)

more..

Author keywords

8 methoxypsoralen; Anti TNF therapy; Crohn's disease; Extracorporeal photopheresis; Immunomodulators

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE;

ANUS FISTULA; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CROHN DISEASE; DISEASE SEVERITY; EXTRACORPOREAL PHOTOPHERESIS; HUMAN; PHOTOTHERAPY; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; SAFETY; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; C-REACTIVE PROTEIN; CROHN DISEASE; DIGESTIVE SYSTEM FISTULA; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOXSALEN; MIDDLE AGED; PHOTOPHERESIS; PHOTOSENSITIZING AGENTS; PILOT PROJECTS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 65249129016     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20833     Document Type: Article

References (39)

1. Hanauer SB, Sandborn WJ, Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2001;96:635-643.
2. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980;302:981-987.
3. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. [comment]. N Engl J Med. 1995;332:292-297.
4. Bajaj JS, Saeian K, Varma RR, et al. Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. Am J Gastroenterol. 2005;100:1121-1125.
5. Domenech E, Nos P, Papo M, et al. 6-Mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine. Scand J Gastroenterol. 2005;40:52-55.
6. D'Haens G, Daperno M. Advances in biologic therapy for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep. 2006;8:506-512.
7. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
8. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333.
9. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357:228-38.
10. Schreiber S, Rutgeerts P, Fedorak RN, et al. CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005;129:807-818.
11. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-936.
12. Thayu M, Markowitz JE, Mamula P, et al. Hepatosplenic T-cell lymphoma in an adolescent patient after immunosuppressant and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr. 2005;40:220-222.
13. Biancone L, Calabrese E, Petruzziello C, et al. Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat Clin Pract Gastroenterol Hepatol. 2007;4:78-91.
14. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265-267.
15. Savill J, Dransfield I, Gregory C, et al. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol. 2002; 2:965-975.
16. Stuart L, Hughes J. Apoptosis and autoimmunity. Nephrol Dial Transplant. 2002;17:697-700.
17. Aubin F, Mousson C. Ultraviolet light-induced regulatory (suppressor) T cells: an approach for promoting induction of operational allograft tolerance? Transplantation. 2004;77(1 suppl):S29-31.
18. Maeda A, Schwarz A, Kernebeck K, et al. Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen-specific regulatory T cells. J Immunol. 2005;174:5968-5976.
19. Rook AH, Suchin KR, Kao DM, et al. Photopheresis: clinical applications and mechanism of action. J Invest Dermatol Symp Proc. 1999;4: 85-90.
20. McKenna KE, Whittaker S, Rhodes LE, et al. Evidence-based practice of photopheresis a report of a workshop of the British Photodermatology Group and the UK Skin Lymphoma Group. Br J Dermatol. 2006;154: 7-20.
21. Greinix HT, Volc-Platzer B, Kalhs P, et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graftversus-host disease: a pilot study. Blood. 2000;96:2426-2431.
22. Greinix HT, Knobler RM, Worel N, et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica. 2006;91: 405-408.
23. Couriel D, Hosing C, Saliba R, et al. Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work? Biol Blood Marrow Transplant. 2006;12(1 suppl 2):37-40.
24. Bisaccia E, Palangio M, Gonzalez J, et al. Treatment of extensive chronic graft-versus-host disease with extracorporeal photochemotherapy. J Clin Apher. 2006;21:181-187.
25. Dall'Amico R, Murer L. Extracorporeal photochemotherapy: a new therapeutic approach for allograft rejection. Transfus Apher Sci. 2002; 26:197-204.
26. Meloni F, Cascina A, Miserere S, et al. Peripheral CD4(+)CD25(+) TREG cell counts and the response to extracorporeal photopheresis in lung transplant recipients. Transplant Proc. 2007;39:213-217.
27. Biagi E, Di Biaso I, Leoni V, et al. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. Transplantation. 2007;84: 31-39.
28. Schwarz T. Regulatory T cells induced by ultraviolet radiation. Int Arch Allergy Immunol. 2005;137:187-193.
29. Brimnes J., Allez M, Dotan I, et al. Defects in CD8+ regulatory T cells in the lamina propria of patients with inflammatory bowel disease. J Immunol. 2005;174:5814-5822.
30. Reinisch W, Nahavandi H, Santella R, et al. Extracorporeal photochemotherapy in patients with steroid-dependent Crohn's disease: a prospective pilot study. Aliment Pharmacol Ther. 2001; 15:1313-1322.
31. Greinix HT, Socié G, Bacigalupo A, et al. Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplant. 2006;38:265-273.
32. Byrne CM, Solomon MJ, Young JM, et al. Patient preferences between surgical and medical treatment in Crohn's disease. Dis Colon Rectum. 2007;50:586-597.
33. Peritt D. Potential mechanism of photopheresis in hematopoietic stem cell transplantation. Biol Blood Marrow Trans. 2006;17:7-12.
34. Suchin KR, Cassin M, Washko R, et al. Extracorporeal photochemotherapy does not suppress T- or B-cell responses to novel or recall antigens. J Am Acad Dermatol. 1999;41:980-986.
35. Bladon J, Taylor PC. Extracorporeal photopheresis: a focus on apoptosis and cytokines. J Dermatol Sci. 2006;43:85-94.
36. Rasul I, Wilson SR, MacRae H, et al. Clinical and radiological responses after infliximab treatment for perianal fistulizing Crohn's disease. Am J Gastroenterol. 2004;99:82-88.
37. Sands BE, Blank MA, Patel K, et al. ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol. 2004;2: 912-920.
38. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829-838.
39. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.